Loading patent…
AssigneesAkeso Pharmaceuticals, Inc., AD Pharmaceuticals Co., Ltd.
InventorsYu Xia, Zhongmin Maxwell Wang, Baiyong Li
Estimating the term…
The present invention relates to a bispecific antibody against CTLA4 and PD-1, wherein the antibody is used for treating tumors, is administered in combination with an anti-VEGFR2 monoclonal antibody or an anti-VEGF monoclonal antibody, and comprises a first protein functional region targeting PD-1 and a second protein functional region targeting CTLA4, the first protein functional region being an immunoglobulin and the second protein functional region being a single-chain antibody, or the first protein functional region being a single-chain antibody and the second protein functional region being an immunoglobulin.
An anti-CTLA4-anti-PD-1 bispecific antibody, wherein the anti-CTLA4-anti-PD-1 bispecific antibody is preferably used for treating a tumor;
A unit formulation preferably used for treating a tumor (particularly a malignant tumor), wherein the unit formulation comprises 1-10000 mg (preferably 10-1000 mg, preferably 50-500 mg. 100-400 mg, 150-300 mg. 150-250 mg, or 200 mg) of the anti-CTLA4-anti-PD-1 bispecific antibody according to claim 1, 1-10000 mg (preferably 1-1000 mg, preferably 50-500 mg. 100-400 mg. 150-300 mg, 150-250 mg. 200 mg, or 100 mg) of the component A as defined in claim 1, and optionally one or more drugs for treating a tumor (preferably, the drug is a chemotherapeutic drug or a growth inhibitor (e.g., an alkylating agent, an anthracycline, an anti-hormonal agent, an aromatase inhibitor, an anti-androgen agent, a protein kinase inhibitor, a lipid kinase inhibitor, an antisense oligonucleotide, a ribozyme, an antimetabolite, a topoisomerase inhibitor, a cytotoxin or an anti-tumor antibiotic, a proteasome inhibitor, an anti-microtubule agent, an EGFR antagonist, a VEGF antagonist, an angiopoietin 2 antagonist, a retinoid, a tyrosine kinase inhibitor, a histone deacetylase inhibitor, and a combination thereof), a targeted therapeutic (e.g., a B-raf inhibitor, an MEK inhibitor, a K-ras inhibitor, a c-Met inhibitor, an Alk inhibitor, a phosphatidylin-ositol-3-kinase inhibitor, an Akt inhibitor, an mTOR inhibitor, a VEGF inhibitor, a PARP inhibitor, a double phosphatidylin-ositol-3-kinase/mTOR inhibitor, and a combination thereof), an antibody-drug conjugate (such as maytansine, monomethyl auristatin E, calicheamicin, esperamicin, and a radioisotope chelator), a T cell expressing a chimeric antigen receptor, an antibody or an antigen-binding fragment thereof, an angiogenesis inhibitor, an antineoplastic, a cancer vaccine, an adjuvant and a combination thereof, an antimetabolite, an antibiotic, a plant-based and/or hormonal drug, a platinum-based drug (e.g., cisplatin, carboplatin, and oxaliplatin), adriamycin, cyclophosphamide, paclitaxel (e.g., albumin-bound paclitaxel, liposome paclitaxel, and docetaxel), etoposide, gemcitabine, pemetrexed, capecitabine, olaparib, rucaparib, niraparib, talazoparib, fluzoparib, vinca alkaloid, tamoxifen, megestrol, goserelin, asparaginase, and/or a fluorouracil antineoplastic agent);
A single dose unit, preferably used for treating a tumor (particularly a malignant tumor), and comprising 0.1-10000 mg (preferably 1-1000 mg, preferably 50-500 mg, 100-400 mg. 150-300 mg. 150-250 mg. 200 mg, or 100 mg) of the anti-CTLA4 anti-PD-1 bispecific antibody according to any one of claims 1-10 and 0.1-10000 mg (preferably 1-1000 mg, preferably 50-500 mg. 100-400 mg. 150-300 mg, 150-250 mg, 200 mg, or 100 mg) of the component A as defined in claim 1.
Dependencies are inferred from the claim text.